EPHAR 2024
The Federation of European Pharmacological Societies
9th European Congress of Pharmacology
Final Program
23-26 June 2024

Athens, Greece
Megaron Athens International Conference Centre
ephar2024.org
Welcome Address

Welcome Letter

The **Federation of European Pharmacological Societies** (EPHAR) consists of 29 member societies that collectively have a total of 12,000 individual members across Europe. Eight years after its last in person Congress, EPHAR will welcome pharmacologists from Europe and the world from **June 23-26, 2024** at the **Megaron Athens International Conference Center**, in downtown Athens. We look forward to hosting a diverse crowd of students, early career researchers, as well as late stage accomplished professionals and world-leading authorities. We anticipate the active participation of basic and clinical pharmacologists from academia, as well as biotech innovators and pharma industry scientists.

There is a number of opportunities to get involved with EPHAR2024. We will be accepting abstracts submissions for oral communications and poster presentations until December 2023 and we invite proposals for satellite meetings until January 2024. The scientific sessions at EPHAR2024 include keynote lectures, round tables, panel discussions, workshops, as well as oral and poster sessions, where you can share your expertise and experiences with other attendees. The conference presents a unique opportunity for intra- and interdisciplinary cross-fertilization of ideas and incorporation of new approaches in all areas of drug discovery and development from target identification and validation to clinical science.

We are looking forward to welcoming you to Greece a country famed for its history, its natural beauty and its hospitality. You will be able to taste some of Greece’s ancient and modern culture, while catching up with friends and colleagues, in the events in our social program.

With Best Wishes,

Andreas Papapetropoulos, PhD  
EPHAR President
About EPHAR

Established in 1990, the Federation of European Pharmacological Societies, a non-profit association, set as its mission to advance research and education in Pharmacology and related sciences and to promote co-operation between National/Regional Pharmacological Societies in Europe and surrounding countries. Fundamental principle of EPHAR is that nothing done by, or in the name of, the federation shall detract from autonomy of any of the participating societies. As to achieve its objects, the Federation undertakes the follow actions:

✓ Hold and arrange instructional courses and training programs in matters connected with pharmacology;
✓ Facilitate the exchange of scientific information between European pharmacologists by encouraging the holding of joint meetings between European member societies and by other appropriate means, like the periodical European congresses of pharmacology;
✓ Collect, disseminate information and encourage the participation to important activities organized by member societies. This will include the production of a calendar of the National and joint meetings of each European society;
✓ Establish common standards for basic courses in pharmacology;
✓ Encourage scientific collaboration between member societies by appropriate means.

About HSBCP

The Hellenic Society of Basic and Clinical Pharmacology is a non-profit scientific society which, for the last three decades, has been supporting the dissemination and advancement of the science of Pharmacology in Greece. The Society's aims include informing, supporting, and promoting scientists in the fields of basic and clinical pharmacology, be it at research or service providing level, as well as the promotion of scientific associations and collaborations, in Greece and abroad.

The Society organizes congresses, meetings and seminars and participates actively in international scientific events concerning Pharmacology in general, taking particular consideration of its younger scientist-members.

The Society is a full member of the Federation of European Pharmacological Societies (EPHAR), the International Union of Basic and Clinical Pharmacology (IUPHAR) and the European Association for Clinical Pharmacology and Therapeutics (EACPT), with official representation in working groups and executive committees.

The Society believes at the great potential of the science of Pharmacology and of its contribution to national development, while it welcomes the support and contribution of all interested parties in achieving its aims.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00-14:00</td>
<td><strong>INDUSTRY SESSION: Cannabidiols, the Westward Movement of Botanicals</strong></td>
<td><strong>MC3 Hall</strong></td>
<td><strong>A. Wallace Hayes, Julia Hoeng</strong></td>
</tr>
<tr>
<td>12:00-12:20</td>
<td>The Value of Biosynthetic Cannabinoids for Drug Development</td>
<td></td>
<td>Zohar Koren</td>
</tr>
<tr>
<td>12:20-12:40</td>
<td>Sustainable Operating Model of Medical Cannabis in Thailand</td>
<td></td>
<td>Pornchai Padmindra</td>
</tr>
<tr>
<td>12:40-13:00</td>
<td>Safety of Cannabidiols</td>
<td></td>
<td>Blaine Philips</td>
</tr>
<tr>
<td>13:00-13:20</td>
<td>Cannabidiol as a Mainstream Medicine: Beyond Dravet and Lennox-Gastaut</td>
<td></td>
<td>Peter Pressman</td>
</tr>
<tr>
<td>13:20-13:40</td>
<td>Therapeutic Prospects of Cannabinoids in the Immunomodulation of Prevalent Autoimmune Disease</td>
<td></td>
<td>Sandra Santander González</td>
</tr>
<tr>
<td>13:40-14:00</td>
<td>The Anti-Inflammatory/Wound Healing Effects of CBD and Thai Traditional Medicine</td>
<td></td>
<td>Sakan Warinhomhoun</td>
</tr>
<tr>
<td>14:00-15:00</td>
<td><strong>Opening Ceremony</strong></td>
<td><strong>Trianti Hall</strong></td>
<td></td>
</tr>
<tr>
<td>15:00-16:00</td>
<td><strong>Plenary 1</strong></td>
<td><strong>Trianti Hall</strong></td>
<td></td>
</tr>
<tr>
<td>16:00-16:30</td>
<td><strong>Break</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**16:30-18:00 | MC3 Hall**

**Advancements in Longevity Pharmacology: Bridging Animal Models and Human Healthspan**

*Organized by the Portuguese Society of Pharmacology*

*Chairs: Claudia Cavadas, Maria José Diógenes*

16:30-17:00 Pharmacological interventions with potential for extending human healthspan  
Claudia Cavadas

17:00-17:30 Future directions of longevity pharmacology research  
João Pedro Magalhães

17:30-18:00 Round Table and Discussion

**16:30-18:30 | Trianti Hall**

**Pharmacogenomics and Personalized Medicine**

*Organized by the European Society of Pharmacogenomics and Personalized Therapy*

*Chairs: Vangelis Manolopoulos, Sanja Stankovic*

16:30-16:50 Pharmacogenomics of HLA-Related Adverse Drug Reactions  
Ann K. Daly

16:50-17:10 Implementation of Pharmacogenetics in Health Systems: a View from European Regulation and the Example of Incorporation in Spain  
Adrián Llerena

17:10-17:30 Pharmacogenomics and Endogenous Biomarkers for OATP1B1  
Mikko Niemi

17:30-17:50 Omics Approaches for Personalization of Anticoagulant Drug Therapy  
Georgia Ragia

17:50-18:10 Optimizing Drug Therapy using a DNA-Passport for Medication  
Ron H.N. van Schaik

18:10-18:30 Discussion

**18.30 Welcome Reception | Musses Foyer**
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Chairs</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:45</td>
<td>Keynote</td>
<td>MC3 Hall</td>
<td>Chairs: Antonis Goulas, Eeva Moilanen</td>
<td>Multi- and poly-pharmacology of carbonic anhydrase inhibitors Claudiu Supuran</td>
</tr>
<tr>
<td>09:00-09:45</td>
<td>Keynote</td>
<td>Trianti Hall</td>
<td>Chairs: Giuseppe Cirino, Maria Diógenes</td>
<td>Targeting neurotrophin receptors in Alzheimer’s Disease Achilleas Gravanis</td>
</tr>
<tr>
<td>09:45-10:15</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Erectile dysfunction induced by Vitamin D deficiency and alcoholism Francisco Pérez Vizcaíno  
Modulation of dopaminergic pathways to treat sexual dysfunction Ulf Simonsen  
The Impact of Empagliflozin in Diabetic Erectile Dysfunction: H2S-Mediated Benefits Gulcan Demir |
10:15-12:15 | Trianti Hall
Molecular Insights into Signal Transduction of G Protein-Coupled Receptors
Organized by the German Society for Pharmacology

Chairs: Christoph Klenk, Constantine Tamvakopoulos

10:15-10:35 Novel insights into the function and inhibition of intrinsically β-arrestin-biased 7TM receptors
Andy Chevigne

10:35-10:55 Genetic code expansion for structural and dynamic studies of GPCRs in living cells
Irene Coin

10:55-11:15 Exploiting data-driven approaches to facilitate G protein-coupled receptor pharmacology
Assoc. Alexander Hauser

11:15-11:35 The elusive pharmacology of the Super Conserved Receptors Expressed in the Brain
Julien Hanson

Glória Queiroz

11:55-12:15 Discussion

10:15-12:15 | MC2 Hall
Molecular Pharmacology of Cancer and Angiogenesis
Organized by the Hellenic Society of Basic and Clinical Pharmacology

Chairs: Evangelia Papadimitriou, Stavros Topouzis

10:15-10:45 Targeting vascular function to treat glioblastoma
Anna Dimberg

10:45-11:15 Targeting mitochondria to inhibit angiogenesis and treat cancer
Dr Stéphanie Herkenne

11:15-11:45 Non-coding RNAs as potential therapeutic targets in gut disease and cancer
Christos Polytarchou

11:45-12:15 Harnessing the potential of myeloid cells in liver cancer: a matter of genetics and combinations
Serena Vegna

12:15-12:45 Lunch Break

12:45-13:45 Poster Session 1
13:45-15:45 | MC3 Hall
Targeting Molecular Networks for Drug Discovery
Organized by the Hungarian Society for Experimental and Clinical Pharmacology

Chairs: Peter Ferdinandy, Zsuzsanna Helyes

13:45-14:15 Importance of miRNA-mRNA networks for discovery and development of miRNA-therapeutics
Bence Ágg

14:15-14:45 Non-coding RNA molecular networks: Implications in drug discovery and diagnosis in the brain-heart axis
Yvan Devaux

14:45-15:15 Network Approaches for Charting the Transcriptomic and Epigenetic Landscape: Implications for target discovery
Jörg Menche

15:15-15:45 Network Pharmacology for Drug Repurposing
Harald Schmidt

13:45-15:45 | Trianti Hall
De-risking Secondary Pharmacology Mediated Adverse Effects as a Path to Develop Safer Medicines
Organized by the British Pharmacological Society

Chair: Friedemann Schmidt, Jean-Pierre Valentin

13:45-14:05 Challenges, opportunities and state of the art considerations for in vitro and in silico secondary pharmacology profiling
Jean-Pierre Valentin

14:05-14:25 An IQ-DruSafe secondary pharmacology industry database analysis of current practices, experiences and recommendations for the future
Friedemann Schmidt

14:25-14:45 Translational Pharmacology Case Studies: Intricacies of predicting patient risk from in vitro secondary pharmacology data
Sonia Roberts

14:45-15:05 Analysis of Secondary Pharmacology Submissions to the US
Rebecca Racz

15:05-15:25 Translational Safety meets Pharmacovigilance
Jordi Mestres
13:45-15:45 | MC2 Hall
Unravelling the Signaling Power of Pollutants
Organized by the Dutch Pharmacological Society & German Pharmacological Society

Chairs: Karim Rafie, Martina Schmidt

13:45-14:15 Role of TRP channels in the protection from and removal of pollutants in the lung
Alexander Dietrich

14:15-14:45 Receptors on the Move; The Convergence of Extracellular Vesicle and GPCR Biology
Caitrin Crudden

14:45-15:15 Imaging pollution - Using cryo-EM to elucidate the molecular events affecting beta-2AR signaling by pollutants
Karim Rafie

15:15-15:45 Alterations of microglia function and neuronal metabolism by pollutants: Impact for neurodegenerative disorders
Martina Schmidt

15:45 - 16:15 Coffee Break

16:15-18:15 | MC3 Hall
The Ongoing Revolution on Anti-Obesity Pharmacological Therapies: Novel Perspectives and Potential Targets
Organized by the Italian Society of Pharmacology

Chairs: Mariarosaria Bucci, Adele Romano

16:15-16:45 Anti-obesity effects of oleoylethanolamide: from metabolic observations to the regulation of eating behaviour
Silvana Gaetani

16:45-17:15 "Amylin & Co." as aid for weight management: from the periphery to the central nervous system
Thomas Lutz

17:15-17:45 Dual agonists of the paracannabinoid and cannabinoid system as novel pharmacological tools to control metabolism
Fernando Antonio Rodriguez De Fonseca

17:45-18:15 Modifications in adipogenesis and remodeling of adipose tissue as potential strategies to overcome obesity
Antonio Vidal-Puig
16:15-18:15 | Trianti Hall

Drug Discovery and Therapeutic Innovation for the Treatment of COPD

Chair: Clive Page

16:15-16:45   Novel drug targets in COPD
              Ian Adcock

16:45-17:15   Ensifentrine, a novel bifunctional drug for the treatment of COPD
              Clive Page

17:15-17:45   Early experimental medicine studies for investigating new drugs for COPD
              Simon Pitchford

17:45-18:15   The burden of unmet needs in COPD
              Wisia Wedzicha

16:15-17:45 | MC2 Hall

Alpha-Synuclein in Parkinson's Disease and Disease-Modifying Strategies for Non-Motor Symptoms

Organized by the Turkish Pharmacological Society

Chairs: Nezahat Tuğba Durdu-Kandilci, Leonidas Stefanis

16:15-16:45   Alpha synuclein as a therapeutic target in Parkinson's Disease and related synucleinopathies
              Leonidas Stefanis

16:45-17:15   Modeling non-motor symptoms of alpha-synucleinopathy targeting autophagic pathway with rapamycin
              Banu Cahide Tel

17:15-17:45   Uncovering a new molecular brake of neuronal plasticity: the role of nitric oxide and TRKB signaling
              Caroline Biojone

18:15-19:00 Keynote | MC3 Hall

Chairs: Constantine Tamvakopoulos, Teresa Tejerina

Targeting of pathological ERK1/2 signaling
Kristina Lorenz

18:15-19:00 Keynote | Trianti Hall

Chairs: Vangelis Manolopoulos, Thomas Wieland

Hallmarks of GPCR Allostery: Structure, Function and Beyond
Arthur Christopoulos

19:00-20:30 EPHAR Council Meeting | MC3.4 Hall
Tuesday, June 25, 2024

09:00-09:45 Keynote | MC3 Hall

Chairs: Peter Ferdinandy, George Liapakis

Efficacy and biased agonism at the Class B1 glucagon-like peptide-1 (GLP-1) GPCR
Patrick Sexton

09:00-09:45 Keynote | MC2 Hall

Chairs: Thomas Griesbacher, Constantine Tamvakopoulos

The expanding universe of gasotransmitters: physiology, pathophysiology and pharmacological applications
Csaba Szabo

09:45-10:15 Coffee Break

10:15-11:15 | MC3 Hall
Pharmacological Modulation of Autophagy in Aging and Neurodegenerative Diseases
Organized by the Italian Society of Pharmacology

Chairs: Agnese Secondo, Elisabetta Panza

10:15-10:45 Decoding molecular mechanisms linked to aging- and disease-related processes: a mitochondrial perspective
Daniele Bano

10:45-11:15 Pharmacological modulation of Lysosomal channels in ALS: new perspectives
Agnese Secondo

11:15-11:45 Autophagic mechanisms in ageing and neurodegeneration
Nektarios Tavernarakis

10:15-12:15 | Trianti Hall
Cannabis-Based Medicines for Inflammation – From Basic Concepts to Pre-Clinical Studies

Chairs: Nadine Godsman, Cherry Wainwright

10:15-10:45 Molecular Targets for Anti-inflammatory Effects of Cannabidiol
Hang Ma

10:45-11:15 Cannabidiol and inflammation-resolving lipid Mediators
Franca Marino

11:15-11:45 Pre-clinical studies on CBD Oil and cardiac fibrosis
Nadine Godsman

11:45-12:15 Pre-clinical studies on Cannabidiol and inflammatory pain
Karin Westlund-High
10:15-10:45 | MC2 Hall
From Regulators to Patients: The Journey of a Medicine in Greece

Chair: Andreas Papapetropoulos
From regulators to patients: the journey of a medicine in Greece
Georgios Panoutsopoulos

12:15-12:45 Lunch Break

12:45-13:45 Poster Session 2

13:45-15:45 | MC3 Hall
Natural Product Pharmacology

Chairs: Angelo Fontana, Robert Fuerst

13:45-14:15 Immunotherapeutic Sulfur-containing Marine Natural Products
Angelo Fontana

14:15-14:45 Indispensable then and now - natural products as tools in drug research
Robert Fuerst

14:45-15:15 Metabolism and bioavailability aspects in bioactive natural products
Maria Halabalaki

15:15-15:30 Discovery of natural product derivative triptolidiol as a direct NLRP3 inhibitor by decreasing K63-specific ubiquitination
Ying Wang

15:30-15:45 A small natural molecule induces non-enzymatic NQO1-dependent necrosis in cancer cells through the JNK1/2/Iron/PARP/calcium pathway
Xiuping Chen

13:45-15:45 | Trianti Hall
Student-Centred Learning, Student Engagement and the Student Experience

Chairs: Betty Exintaris, Nilushi Karunaratne

13:45-14:15 Engaging students through teamwork and inclusive practice
Nilushi Karunaratne & Betty Exintaris

14:15-14:45 Cognitive, emotional, and behavioural student engagement - how do we achieve them?
Paul White

14:45-15:15 Virtual reality animations in pharmacology education – student experience and perception of learning
Jon Andsnes Berg & Trond Trætteberg Serkland

15:15-15:45 Teaching about ethnicity in pharmacology - implications for the wider curriculum
Jennifer Koenig & Olusola Olafuyi
13:45-15:15 | MC2 Hall
Career Paths in Pharmacology
Organized by the Early Career Researcher Group of EPHAR

Chair: Kyriaki Thermos

13:45-14:15  Mining cysteineolysis in endothelial cell fates
            Sofia-Iris Bibli

14:15-14:45  Tachykinin research: old family, new directions
            Éva Borbély

14:45-15:15  It takes two to tango: pharmacology and passion
            Patrycja Nowak-Sliwinska

15:45-16:15 Coffee Break

16:15-18:15 | MC3 Hall
Current Developments and Approaches in Ion Channel Pharmacology
Organized by the Swiss Society of Pharmacology and Toxicology

Chairs: Stephan Kellenberger, Stephan Von Gunten

16:15-16:45  Pharmacology and modulation of the P2X7 purinergic receptor channel
            Annette Nicke

16:45-17:15  Using photoswitchable compounds to study the involvement of TREK channels in pain and migraine
            Guillaume Sandoz

17:15-17:45  Development of ligand-gated ion channel drug screening assays across multiple automated patch-clamp platforms
            Fitzwilliam Seibertz

17:45-18:15  Insights into the activation mechanism of acid-sensing ion channels (ASICs)
            Stephan Kellenberger

16:15-18:15 | Trianti Hall
Exploiting Immunopharmacology in Different Diseases
Organized by the International Union of Basic and Clinical Pharmacology

Chair: Francesca Levi-Schaffer, Katerina Tiligada

            Anna Brichkina

16:45-17:15  Immunopharmacology in Allergy: CD300a an inhibitory receptor expressed on inflammatory cells in allergy and beyond
            Francesca Levi-Schaffer

17:15-17:45  Immunopharmacology in Asthma: Immunopharmacological interventions in treating asthma. Is it all about inflammation?
            Emily Swindle

17:45-18:15  Immunopharmacology in Ocular Inflammation
            Katerina Tiligada
16:15-18:15 | MC2 Hall
Oral Communications I

Chairs: Mariarosaria Bucci, Achilleas Gravanis

16:15-16:30  OC01. E2F Transcription Factor 2 (E2F2) Facilitates Atherosclerosis Through CCAAT Enhancer Binding Protein β Mediated Endothelial Cell Inflammation

Wu Y¹, Huang X¹, Huang Y¹, Wang L¹  
¹Department of Biomedical Sciences, City University of Hong Kong, Kowloon, China

16:30-16:45  OC02. Cyst(e)ine import and catabolism preserve endothelial chromatin accessibility and promote vessel growth

Mettner J¹,², Drekolia M¹,², Wittig J¹,², Siragusa M², Weigert A³, Fleming I², Günther S⁴, Looso M⁴, Hecker D⁵, Schulz M⁵, Hu J¹,², Bibli S¹,²  
¹Department for Vascular Dysfunction, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, ²Institute for Vascular Signalling, Goethe University, Frankfurt, Germany, ³Institute for Biochemistry I, Faculty of Medicine, Goethe University, Frankfurt am Main, Germany, ⁴Cardio-Pulmonary Institute (CPI) Bioinformatics and Deep Sequencing Platform, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany, ⁵Department of Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhing University of Science and Technology, Wuhan, China

16:45-17:00  OC03. Investigating the cardioprotective potential of novel Sirtuin agonists. Sirtuin 5 emerges as a new target in mitigating myocardial ischemia-reperfusion injury

Castiello C¹, Efentakis P¹, Symeonidi L¹, Chania C¹, Tasouli A², Kostomitsopoulos N³, Mikros E⁴, Zwergel C⁵, Valente S⁵, Mai A⁵, Andreadou I¹  
¹Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece, ²Onassis Cardiac Surgery Center, Athens, Greece, ³Biomedical Research Foundation of the Academy of Athens, Athens, Greece, ⁴Department of Pharmaceutical Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece, ⁵Department of Drug Chemistry and Technologies; University of Rome; Sapienza, Rome, Italy

17:00-17:15  OC04. Effect of SGLT2i on heart tissue in diabetic rats: SIRT1 connection

Kizrak U¹, Özsarlık-Süzer G¹, Shamamedov K¹, Alan-Albayrak E¹, Glaker-Micili S², Cavdar Z³, Ural C³, Cetinkalp S⁴, Bilici-Guler G², Kerry Z¹  
¹Ege University Faculty of Pharmacy Department of Pharmacology, Izmir, Turkey, ²Dokuz Eylül University, Faculty of Medicine, Department of Histology and Embryology, Izmir, Turkey, ³Dokuz Eylül University, Faculty of Medicine, Department of Molecular Medicine, Izmir, Turkey, ⁴Ege University, Faculty of Medicine, Department of Endocrinology and Metabolic Diseases, Izmir, Turkey

17:15-17:30  OC05. The functional interaction of Apolipoprotein A2 with the metabolic system of apolipoprotein E-rich lipoproteins in the regulation of the lipid profile

Kakafoni G¹, Mparnia V¹, Giannatou K¹, Zvintzou E¹,², Kypros K¹, Gafencu A², Ioana Madalina F²  
¹Pharmacology Laboratory, Department of Medicine, School of Health Sciences, University of Patras, Patras, Greece, ²Institute of Cellular Biology and Pathology “Nicolae Simionescu” of the Romanian Academy, Bucharest, Romania
17:30-17:45  OC06. Potential repurposing of the SYK inhibitor Fostamatinib in a diet-induced model of insulin resistance: an in vivo study

**Aimaretti E**¹, Porchietto E², Ferreira Alves G², Einaudi G¹, Collotta D³, Rubeo C¹, Marzani E³, Mastrocola R¹, Cifani C², Aragno M¹, Collino M³

¹Department of Clinical and Biological Sciences, University of Turin, Turin, Italy, ²School of Pharmacy, University of Camerino, Camerino, Italy, ³Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Turin, Italy

17:45-18:00  OC07. Pharmacological inhibition of cyclin-dependent kinase 9 (CDK9) ameliorates metabolic abnormalities evoked by chronic consumption of hypercaloric diet in mice

**Porchietto E**¹, Collotta D², Aimaretti E³, Ferreira Alves G¹, Einaudi G¹, Marzani E², Rubeo C³, Mastrocola R³, Aragno M³, Cifani C¹, Collino M²

¹Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy, ²Department of Neurosciences “Rita Levi Montalcini”, University of Turin, Turin, Italy, ³Department of Clinical and Biological Sciences, University of Turin, Turin, Italy

18:00-18:15  OC08. FKBP5 rs4713916 could serve as a genetic predictor of interindividual different response to inhaled corticosteroids in patients with chronic obstructive pulmonary disease

**Ntenti C**¹, Papakonstantinou E³, Grize L², Stolz D², Goulas A¹

¹1st Laboratory of Pharmacology, Department of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, ²Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland, ³Clinic of Respiratory Medicine, Faculty of Medicine, University of Freiburg, Freibourg, Germany

18:15-19:00 Keynote | MC3 Hall

**Chairs: Ioannis Charalampopoulos, Francesca Levi-Schaffer**

Exploiting Mitochondrial Dysfunction for Cancer Therapy

Evripidis Gavathiotis

18:15-19:00 Keynote | MC2 Hall

**Chairs: Maria Konstandi, Andreas Papapetropoulos**

Selective protein degraders (PROTACs) as new pharmacological modalities and chemical tools for target validation

Stefan Knapp
Wednesday, June 26, 2024

9:00-10:30 Poster Session 3

10:00-10:30 Coffee Break

10:30-12:30 | MC3 Hall
Unraveling the Complexities of Systemic Inflammation: Insights from Sepsis, Trauma, and AI/Machine Learning

Organized by the European Shock Society and the Hellenic Institute for the Study of Sepsis

Chairs: Evagelos Giamarellos-Bourboulis, Borna Reija

10:30-10:50 Systemic Inflammation, Sepsis and Immunoparalysis; Inevitable or reversible? Antigone Kotsaki

10:50-11:10 Trauma-Induced Systemic Inflammation - Friend or Foe? Borna Relja

11:10-11:30 Molecular Profiling of Pneumonia and Sepsis using Machine Learning and Al Brendon Scicluna

11:30-11:50 Pharmacological inhibition of CK2 with Silmitasertib protects against sepsis-induced cardiovascular dysfunction by interfering with nitric oxide release Gustavo Ferreira Alves

11:50-12:10 Spleen Tyrosine Kinase: a novel pharmacological target for sepsis-induced cardiac dysfunction and multi-organ failure Chiara Verra

12:10-12:30 Discussion

10:30-12:30 | Trianti Hall
Pharmacological Landscape of Neuro-Immune Interactions: Insights and Implications

Organized by the American Society of Pharmacology and Experimental Therapeutics

Chairs: Habibeh Khoshboeui, Stephanie Matt

10:30-11:00 Role of dopamine on immune response and bone remodeling in rheumatoid arthritis Silvia Capellino

11:00-11:30 The Role of Dopamine Transporter in Peripheral Immunity: Insights into Immune Cell Regulation Habibeh Khoshboeui

11:30-12:00 Dopaminergic modulation of the immune response: lessons from Parkinson's Disease Franca Marino

12:00-12:30 Antidepressant and Depression-mediated Myeloid Inflammation and HIV Viral Dynamics Stephanie Matt

10:30-12:30 | MC2 Hall
10:30-10:45  OC09. The Role of DHEA(s) in Dementia: Insights from Cellular and Animal Models and Human Patients
Vuic B1, Milos T1, Tudor L1, Konjevod M1, Farkas V1, Nikolak Perkovic M1, Nedic Erjavec G1, Knezovic A2, Osmanovic Barilar J3, Szabo A3, Farkas S3, Zelen A3, Uzun S4, Kozumplik O4, Mimica N4, Svoj Strac D1
1Laboratory of Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, Zagreb, Croatia, 2Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia, 3Centre for Neuroscience, Szentágothai Research Centre, Institute of Physiology, Medical School, University of Pécs, Pecs, Hungary, 4Department for Biological Psychiatry and Psychogeriatrics, University Psychiatric Hospital Vrapce, Zagreb, Croatia

10:45-11:00  OC10. Dissecting the role of p75 pan-neurotrophin receptor in the hyperglycemia – induced neuropathology using a human iPSC-based model.
Chanoumidou K1,2, Zota I1,2, Papadopoulou M1,2, Gravanis A1,2, Charalampopoulos I1,2
1Pharmacology Dept., Medical School, University of Crete, Heraklion, Greece, 2Institute of Molecular Biology and Biotechnology of the Foundation for Research and Technology Hellas (IMBB-FORTH), Heraklion, Greece

11:00-11:15  OC11. The selective positive allosteric modulator (PAM) of the glutamate transporter EAAT2 efficiently relieves pain and pruritus of different origins and potentiates opioid-induced analgesia
Mogilski S1, Kubacka M1, Sapa J1, Rapacz A1, Jakubiec M2, Abram M2, Kamiński K2
1Department of Pharmacodynamics, Faculty of Pharmacy, Medical College, Jagiellonian University, Kraków, Poland, 2Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland

11:15-11:30  OC12. Design and biological characterization of new biologic (Ab-IPL-IL-17) for IL-17s-mediated diseases
Saviano A1, Mansour A2, Raucci F1, Merlino F3, Marigliano N1, Schettino A1, Vellecco V3, Cirino G1, Bucci M1, McGcttrick H4, Grieco P3, Iqbal A2, Maione F1
1ImmunoPharmaLab, Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy, 2Institute of Cardiovascular Sciences (ICVS), College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK, 3Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy, 4Institute of Inflammation and Ageing (IIA), College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

11:30-11:45  OC13. The anti-inflammatory cytokine IL-37 plus IL-15 enhances human NK cells antitumor functions by interacting with IL-1R8
Landolina N1, Mariotti F1, Pelosi A1, D’Oria V2, Ingegnere T1, Alicata C1, Vacca P3, Moretta L1, Maggi E1
1Tumor Immunology Unit, Bambino Gesù Children’s Hospital, IRCCS 00146 Rome, Italy, 2Research Laboratories, Confoocal Microscopy Core Facility, Bambino Gesù Children’s Hospital, IRCCS, 00146 Rome, Italy, 3 Immunology Research Area, Innate Lymphoid Cells Unit, Bambino Gesù Children’s Hospital, IRCCS, 00146 Rome, Italy

11:45-12:00  OC14. Crizotinib inhibits mTORC1 activation, protein synthesis and endothelial cell activation by pleiotrophin or PTPRZ1 deletion
Mourkogianni E1, Ntenekou D1, Enake M1, Xanthopoulos A1, Kastana P1, Papadimitriou F1
1University of Patras, Patras, Greece
12:00-12:15  OC15. Observational studies of repurposing old drugs for new indications: The example of metformin to treat breast cancer

Suissa S$^{1,2}$
$^{1}$McGill University, Montreal, Canada, $^{2}$Jewish General Hospital, Montreal, Canada

12:15-12:30  OC16. Emerging roles of 3-MST in colon cancer

Ascencao K$^1$, Szabo C$^1$
$^1$University of Fribourg, Fribourg, Suisse

13:00-14:00 Paoletti Award Speech | Trianti Hall

Chairs: Giuseppe Cirino, Maria-Jesus Sanz

Reprogramming the synapse: from basic findings to translational research

Monica DiLuca

14:00-15:30 Closing Ceremony | Trianti Hall
Gold Sponsors

DR.CBD
MEDICAL SCIENCE FOR A BETTER LIFE

Silver Sponsors

Verduci Editore

BJP
British Journal of Pharmacology

Supporters

IU PHAR
INTERNATIONAL UNION OF BASIC AND CLINICAL PHARMACOLOGY
Exhibitors

MCE®

SIF

PROTAVIO

BRITISH PHARMACOLOGICAL SOCIETY

P. Zafiropoulos s.a.

Flowcytogen Laboratories s.a.

Innoprot

Z Elektronika
Το ΚΛΙΚ ΤΗΣ ΕΜΠΙΣΤΟΣΥΝΗΣ

Trimbow συσκευή εισπνοής
NEThaler
ΤΟ ΚΛΙΚ ΤΗΣ ΕΜΠΙΣΤΟΣΥΝΗΣ"²"

1. Trimbow® συσκευή εισπνοής NEThaler® ΓΧΠ

*Το «ΚΛΙΚ» σχετίζεται με την ενεργοποίηση της συσκευής εισπνοής NEThaler®, το απόει προβλέπει αυτός ασθενείς ότι η πλήρης δόση έχει απελευθερωθεί και δεν αποτελεί διαβεβαίωση ορθής λήψης της δόσης από τον ασθενή.

Οι αντιανευρίστες, οι προφυλάξεις και οι ανεπάγγελτες ενέργειες περιλαμβάνονται στην ΓΧΠ του προϊόντος.
Για την Περίληψη Χαρακτηριστικών του Προϊόντος πατήστε εδώ

CHIESI HELAS A.E.B.E.
Pλ. Γερογκλαύτου & Ρένου Πλάγη 1,
Τ.Κ.: 174 55, Άγιος Ανατολικός, Ελλάδα
Αρ. ΓΕΜΗ 002669501000
Τ.: +30 210 61 79 763, F.: +30 210 61 79 786
E.: chiesihellas@chiesi.com,
Ε. τμήματος φαρμακοκανονισμού: pharmacovigilance.gr@chiesi.com
www.chiesi.gr
TRNEXT-ADV2-1-01/2023

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και αναφέροντες:
ΟΛΕΣ τις ανεπάγγελτες ενέργειες για ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΩΤΡΙΝΗ ΚΑΡΤΑ»
Since 1970, Verduci Editore has been a leading force in sharing medical-scientific knowledge globally. As a pioneering publishing house, we specialize in creating encyclopedic treatises, comprehensive manuals, and esteemed international open-access journals. Join us in advancing global health and knowledge.

Scan the QR code for more information about our books and journals

www.verduci.it
info@verduci.it
Via Gregorio VII, 186 - 00165 Roma
+39 06 39375224
Priming Drugs for Success
We specialize in preclinical testing using mouse disease models with humanized therapeutic targets

Therapeutic Areas
- Acute Inflammation
- Arthritis
- Cancer
- Fibrosis
- Infectious Diseases
- Inflammatory Bowel Disease
- Lupus
- Multiple Sclerosis
- Osteoporosis
- Psoriasis
- Spondyloarthritis

CRO Preclinical Services
- In vivo efficacy studies
- In vitro screening
- Ex vivo testing
- PK/PD studies

Analysis Methods
- Histology
- Molecular assays
- Cellular assays
- Immunoassays
- Immunophenotyping

Our clients around the world

www.biomedcode.com